drugset / Trial / NCT01087983

Lapatinib With Sirolimus or Metformin

NCT01087983

Phase 1 Completed 111 enrolled M.D. Anderson Cancer Center
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of 2 different combinations of drugs that can be given to patients with advanced cancer. The first combination of drugs is Tykerb (lapatinib) and Rapamune (sirolimus), and the second combination is lapatinib and Glucophage (metformin). The safety of these drug combinations will also be studied.

Timeline

Start
2010-03
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lapatinib Small molecule 500 mg Oral
Subject Metformin Small molecule 1000 mg Oral
Subject Sirolimus Small molecule 1 mg Oral

Indications

No indication recorded.